Objective: To assess the appropriateness of laboratory testing intervals and antiphospholipid syndrome (APS) incidence.
Methods: Between January 2010 and August 2022, insurance claims data of patients with disease codes for other thrombophilia (D68.6) and APS (V253) were retrieved in South Korea.